Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine.


Journal

Chemico-biological interactions
ISSN: 1872-7786
Titre abrégé: Chem Biol Interact
Pays: Ireland
ID NLM: 0227276

Informations de publication

Date de publication:
01 May 2019
Historique:
received: 11 12 2018
revised: 21 02 2019
accepted: 05 03 2019
pubmed: 13 3 2019
medline: 14 5 2019
entrez: 13 3 2019
Statut: ppublish

Résumé

Phenelzine (β-phenylethylhydrazine) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic properties. It possesses a number of important pharmacological properties which may alter the effects of oxidative stress. After conducting a comprehensive literature search, the authors of this review paper aim to provide an overview and discussion of the mechanisms by which phenelzine may attenuate oxidative stress. It inhibits γ-aminobutyric acid (GABA) transaminase, resulting in elevated brain GABA levels, inhibits both MAO and primary amine oxidase and, due to its hydrazine-containing structure, reacts chemically to sequester a number of reactive aldehydes (e.g. acrolein and 4-hydroxy-2-nonenal) proposed to be implicated in oxidative stress in a number of neurodegenerative disorders. Phenelzine is unusual in that it is both an inhibitor of and a substrate for MAO, the latter action producing at least one active metabolite, β-phenylethylidenehydrazine (PEH). This metabolite inhibits GABA transaminase, is a very weak inhibitor of MAO but a strong inhibitor of primary amine oxidase, and sequesters aldehydes. Phenelzine may ameliorate the effects of oxidative stress by reducing formation of reactive metabolites (aldehydes, hydrogen peroxide, ammonia/ammonia derivatives) produced by the interaction of MAO with biogenic amines, by sequestering various other reactive aldehydes and by inhibiting primary amine oxidase. In PC12 cells treated with the neurotoxin MPP

Identifiants

pubmed: 30857888
pii: S0009-2797(18)31724-1
doi: 10.1016/j.cbi.2019.03.003
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Free Radical Scavengers 0
Monoamine Oxidase Inhibitors 0
Monoamine Oxidase EC 1.4.3.4
Phenelzine O408N561GF

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-147

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Glen Baker (G)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada. Electronic address: glen.baker@ualberta.ca.

Dmitriy Matveychuk (D)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada. Electronic address: dmitriym@ualberta.ca.

Erin M MacKenzie (EM)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada. Electronic address: emm3@ualberta.ca.

Andrew Holt (A)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada. Electronic address: aholt@ualberta.ca.

Yanlin Wang (Y)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada; Department of Medicine (Neurology), University of Alberta, Edmonton, Canada. Electronic address: yanlin.wang8@gmail.com.

Satyabrata Kar (S)

Department of Psychiatry (Neurochemical Research Unit), University of Alberta, Edmonton, Canada; Department of Medicine (Neurology), University of Alberta, Edmonton, Canada. Electronic address: skar@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH